Loading stock data…
Corcept Therapeutics Incorporated (CORT)
$95.36-1.30 (-1.34%)
Market ClosedLast close Jul 24
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corcept Therapeutics Incorporated in the Healthcare sector is trading at $95.36 with a market capitalization of $8.9B. Wall Street consensus targets $106.00 (3 analysts), implying a +11.2% move over the next 12 months. The stock is currently near its 52-week high of $97.63, remaining 55.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $164.90M↓ | $202.13M↓ | $207.64M↑ | $194.43M↑ | $157.21M |
| Gross Profit | $162.02M↓ | $199.58M↓ | $203.04M↑ | $191.00M↑ | $154.81M |
| Operating Income | -$49.60M↓ | $4.49M↓ | $10.22M↓ | $26.68M↑ | $3.42M |
| Net Income | -$31.76M↓ | $24.29M↑ | $19.67M↓ | $35.15M↑ | $20.55M |
Peer Comparison
JNJUNHPFE
Fundamentals
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.42%
Volume
Today's trading volume
859,818
Recent News
Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued?
Corcept Therapeutics (CORT) has attracted fresh attention after a sharp improvement in its earnings outlook, with full year earnings estimates rising significantly and analyst sentiment turning more constructive toward the stock. See our latest analysis for Corcept Therapeutics. Corcept Therapeutics' share price has climbed over recent months, with a 16.9% 1 month share price return and a 107.0% 3 month share price return, while the 5 year total shareholder return of 359.1% reflects a strong...
Corcept Therapeutics (CORT) Is Up 5.3% After Analysts Lift Full-Year Earnings Outlook Significantly
Recently, Corcept Therapeutics received an upgraded Zacks Rank of #2 (Buy) after analysts sharply raised their full-year earnings estimates, reflecting a much stronger profit outlook than previously expected. This improved earnings view has come alongside performance that has far outstripped the broader Medical sector and the Medical – Drugs industry, underlining how quickly sentiment can shift when projections change. We’ll now examine how this strengthened earnings outlook and analyst...
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025.
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.